Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

详细信息    查看全文

• 作者：Prof Ulrich Vogel ; MD^a ; Muhamed-Kheir Taha ; MD^b ; Julio A Vazquez ; PhD^c ; Jamie Findlow ; PhD^d ; Heike Claus ; PhD^a ; Paola Stefanelli ; PhD^e ; Prof Dominique A Caugant ; PhD^f ; Paula Kriz ; MD^g ; Raquel Abad ; PhD^c ; Stefania Bambini ; PhD^h ; Anna Carannante ; BS^e ; Ala Eddine Deghmane ; PhD^b ; Cecilia Fazio ; BS^e ; Prof Matthias Frosch ; MD^a ; Giacomo Frosi ; MSc^h ; Stefanie Gilchrist ; MSc^d ; Marzia M Giuliani ; MSc^h ; Eva Hong ; BSc^b ; Morgan Ledroit ; BSc^b ; Pietro G Lovaglio ; PhD^j ; Jay Lucidarme ; PhD^d ; Martin Musilek ; PhD^g ; Alessandro Muzzi ; MSc^h ; Jan Oksnes ; MSc^f ; Fabio Rigat ; PhD^h ; Luca Orlandi ; PhD^h ; Maria Stella ; PhD^h ; Danielle Thompson ; BSc^d ; Mariagrazia Pizza ; PhD^h ; Rino Rappuoli ; PhD^h ; Davide Serruto ; PhD^h ; Maurizio Comanducci ; MSc^h ; Giuseppe Boccadifuoco ; MSc^h ; John J Donnelly ; PhDⁱ ; Duccio Medini ; PhD^h ; Prof Ray Borrow ; FRCPath^d ; ^{ray.borrow@hpa.org.uk}
• 刊名：The Lancet Infectious Diseases
• 出版年：2013
• 出版时间：May, 2013
• 年：2013
• 卷：13
• 期：5
• 页码：416-425
• 全文大小：450 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

A novel multicomponent vaccine against meningococcal capsular group B (MenB) disease contains four major components: factor-H-binding protein, neisserial heparin binding antigen, neisserial adhesin A, and outer-membrane vesicles derived from the strain NZ98/254. Because the public health effect of the vaccine, 4CMenB (Novartis Vaccines and Diagnostics, Siena, Italy), is unclear, we assessed the predicted strain coverage in Europe.

Methods

We assessed invasive MenB strains isolated mainly in the most recent full epidemiological year in England and Wales, France, Germany, Italy, and Norway. Meningococcal antigen typing system (MATS) results were linked to multilocus sequence typing and antigen sequence data. To investigate whether generalisation of coverage applied to the rest of Europe, we also assessed isolates from the Czech Republic and Spain.

Findings

1052 strains collected from July, 2007, to June, 2008, were assessed from England and Wales, France, Germany, Italy, and Norway. All MenB strains contained at least one gene encoding a major antigen in the vaccine. MATS predicted that 78 % of all MenB strains would be killed by postvaccination sera (95 % CI 63-90, range of point estimates 73-87 % in individual country panels). Half of all strains and 64 % of covered strains could be targeted by bactericidal antibodies against more than one vaccine antigen. Results for the 108 isolates from the Czech Republic and 300 from Spain were consistent with those for the other countries.

Interpretation

MATS analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future.

Funding

Novartis Vaccines and Diagnostics.